Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- NYU Langone Health SystemSugar Amplifies Damage Done to Gut Health by AntibioticsEating sweets while taking antibiotics may worsen the harm done by the drugs to the normal community of bacteria in the gut, a new study found. The work centers on the intestinal microbiome, which harbors bacterial species that co-evolved with...
- China Biopsy Devices Market Report 2026-2034 by Product, Imaging Technology, End User, City, and Company | Image-Guided Diagnostics Propel Market to US$1.16 BillionChina’s biopsy device market gains momentum from cancer screening, minimally invasive innovation, hospital upgrades, government support and cost-effective local manufacturing
- Regulatory Compliance Training for Dietary Supplements in the US, EU and Canada | Navigate Evolving GMP, Labeling and Claims Rules to Reduce Risk and Accelerate Market Access (Aug 12th-Aug 13th, 2026)Boost ROI through GMP compliance, cost-efficient operations, FDA readiness, and reduced risk of warning letters and injunctions.
- Ontario impulsa la innovación en ciencias de la vida en las instalaciones de Piramal Pharma en AuroraPiramal Pharma Solutions ("PPS"), una organización líder mundial de desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd....
- ChemDAQChemDAQ Partners with AHS to Expand Access to Continuous Chemical Vapor Monitoring Across Canadian HealthcarePartnership to Be Showcased at Canadian Association of Medical Device Reprocessing (CAMDR) 2026 in St. John's, Newfoundland & Labrador — ChemDAQ, a leading provider of hazardous gas monitoring solutions, is pleased to announce a new partnership...
- ChemDAQChemDAQ and Proline Medical Partner to Expand Access to Continuous Chemical Vapor Monitoring in Australian HospitalsPartnership Formed as Australia Prepares to Adopt New Workplace Exposure Limits on 1 December 2026 — ChemDAQ, a leading provider of hazardous gas monitoring solutions, is pleased to announce a new partnership with Proline Medical, an Australian...
- PolymarketPolymarket Launches New User Protections and Trust & Safety ProgramNew responsible trading tools, mental health resources and Trust & Transparency Center reinforce Polymarket's commitment to protecting users and its marketplace — Polymarket, the world's largest prediction market platform, today unveiled a suite of...
- LavenderLavender Psychiatry and Ember Health Advance a More Connected Model for Specialized Mental Health CareThe four-year partnership integrates ongoing psychiatric care with specialized IV ketamine treatment, creating a more efficient and coordinated care pathway for patients with depression. — Lavender Psychiatry, the largest nurse-led psychiatry and...
- Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2026.
- Integer Receives Early Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition by KKRCompanies: KKR & Co.Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading global medical device contract development and manufacturing organization (CDMO), today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with the previously announced acquisition of Integer by an affiliate of investment funds managed by KKR (the “Merger”).
- Tokyo Lifestyle Highlights Commitment to Shareholder Returns with Year-End Cash DividendTokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today highlighted its commitment to shareholder returns following the payment of a year-end cash dividend of JPY1.890 per share for the fiscal year ended March 31, 2026.
- Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisEupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”).